HomeProductsBioactive CompoundsEndocrine & Hormonal TargetsGlucocorticoid ReceptorCAS 1034148-04-3
Chemical structure of CAS 1034148-04-3

2,2,2-trifluoro-N-((1S,2R)-2-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-2-(3-methoxyphenyl)-1-methylethyl)acetamide

In Stock•Starting at $103 for 5 mg•Purity ≥ 98%
CAS No.1034148-04-3
MDL No.MFCD26142626
MFC25H21F4N3O3
MW487.40
InChI KeyFCNQMDSJHADDFT-WNSKOXEYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg98%$103In Stock
10 mg98%$169In Stock
25 mg98%$334In Stock
50 mg98%$533In Stock
100 mg98%$906In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1034148-04-3
Product Name2,2,2-trifluoro-N-((1S,2R)-2-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-2-(3-methoxyphenyl)-1-methylethyl)acetamide

Biological Targets

NR3C1

Associated Conditions

asthma·chronic obstructive pulmonary disease
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

RIPK3 inhibitor-AZD5423 alleviates acute kidney injury by inhibiting necroptosis and inflammation.

International immunopharmacology • Vol. 112 • 2022
PMID: 36166972DOI: 10.1016/j.intimp.2022.109262

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.

Journal of medicinal chemistry • Vol. 60, Issue 20 • 2017
PMID: 28937774DOI: 10.1021/acs.jmedchem.7b01215

Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.

Basic & clinical pharmacology & toxicology • Vol. 121, Issue 4 • 2017
PMID: 28212463DOI: 10.1111/bcpt.12768

Documentation

Similar Products